7 April 2022
Diaceutics PLC
("Diaceutics" or "the Company")
Purchase and Sale of Shares and PDMR Shareholdings
Diaceutics PLC, (AIM: DXRX), the diagnostic commercialisation company announces the following Director and PDMR share dealings.
On 5 April 2022, Nick Roberts, CFO of Diaceutics, purchased 39,179 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of £1.015 pence per Ordinary Share. As a result of the purchase, Nick's shareholding is 39,179 Ordinary Shares, representing approximately 0.05 % of the Company's issued share capital.
On 6 April 2022, Deborah Davis, the Chair of Diaceutics, purchased 20,000 Ordinary Shares at an average price of £1.0125 pence per share. As a result of the purchase, Deborah's shareholding is 64,800 Ordinary Shares, representing approximately 0.08 % of the Company's issued share capital.
On 6 April 2022, Charles Hindson, Non-Executive Director of Diaceutics, purchased 20,000 Ordinary Shares at a price of £1.01 pence per share. As a result of the purchase, Charles' shareholding is 63,500 Ordinary Shares, representing approximately 0.08 % of the Company's issued share capital.
Across 5 and 6 April 2022, Philip White, a PDMR, sold 200,000 Ordinary Shares at an average price of £0.989 pence per Ordinary Share. As a result of Philip's sale, the beneficial holding of Philip White and his connected parties in the Company is 1,406,389 Ordinary Shares, representing 1.67 % of the Company's issued share capital.
Enquiries:
|
Diaceutics PLC
|
|
|
Nick Roberts, Chief Financial Officer
|
Via Alma PR
|
|
|
|
|
Stifel Nicolaus Europe Limited (Nomad & Broker)
|
Tel: +44 (0)20 7710 7600
|
|
Ben Maddison
|
|
|
Stewart Wallace
|
|
|
Nick Adams
|
|
|
|
|
|
Alma PR
|
Tel: +44(0)20 3405 0205
|
|
Caroline Forde
|
[email protected]
|
|
Kieran Breheny
|
|
|
Matthew Young
|
|
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
|
|
1
|
Details of the person discharging managerial responsibilities/person closely associated
|
|
a.
|
Name
|
Nick Roberts
|
|
2
|
Reason for notification
|
|
|
a.
|
Position/Status
|
CFO
|
|
b.
|
Initial notification/
Amendment
|
Initial
|
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a.
|
Name
|
Diaceutics PLC
|
|
b.
|
LEI
|
213800VEWQBB39ZB8J81
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
a.
|
Description of the financial instrument, type of instrument
Identification Code
|
Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64
|
|
b.
|
Nature of the transaction
|
Purchase
|
|
c.
|
Price(s) and volume(s)
|
|
Share purchase:
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
£1.015
|
39,179
|
|
|
|
|
d.
|
Date of the transaction
|
5 April 2022
|
|
e.
|
Place of the transaction
|
AIM Market of the London Stock Exchange
|
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
|
|
1
|
Details of the person discharging managerial responsibilities/person closely associated
|
|
a.
|
Name
|
Deborah Davis
|
|
2
|
Reason for notification
|
|
|
a.
|
Position/Status
|
Chair
|
|
b.
|
Initial notification/
Amendment
|
Initial
|
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a.
|
Name
|
Diaceutics PLC
|
|
b.
|
LEI
|
213800VEWQBB39ZB8J81
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
a.
|
Description of the financial instrument, type of instrument
Identification Code
|
Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64
|
|
b.
|
Nature of the transaction
|
Purchase
|
|
c.
|
Price(s) and volume(s)
|
|
Share purchase:
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
£1.01
£1.02
|
15,000
5,000
|
|
|
|
|
d.
|
Date of the transaction
|
6 April 2022
|
|
e.
|
Place of the transaction
|
AIM Market of the London Stock Exchange
|
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
|
|
1
|
Details of the person discharging managerial responsibilities/person closely associated
|
|
a.
|
Name
|
Charles Hindson
|
|
2
|
Reason for notification
|
|
|
a.
|
Position/Status
|
Non-Executive Director
|
|
b.
|
Initial notification/
Amendment
|
Initial
|
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a.
|
Name
|
Diaceutics PLC
|
|
b.
|
LEI
|
213800VEWQBB39ZB8J81
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
a.
|
Description of the financial instrument, type of instrument
Identification Code
|
Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64
|
|
b.
|
Nature of the transaction
|
Purchase
|
|
c.
|
Price(s) and volume(s)
|
|
Share purchase:
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
£1.01
|
20,000
|
|
|
|
|
d.
|
Date of the transaction
|
6 April 2022
|
|
e.
|
Place of the transaction
|
AIM Market of the London Stock Exchange
|
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
|
|
1
|
Details of the person discharging managerial responsibilities/person closely associated
|
|
a.
|
Name
|
Philip White
|
|
2
|
Reason for notification
|
|
|
a.
|
Position/Status
|
PDMR
|
|
b.
|
Initial notification/
Amendment
|
Initial
|
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a.
|
Name
|
Diaceutics PLC
|
|
b.
|
LEI
|
213800VEWQBB39ZB8J81
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
a.
|
Description of the financial instrument, type of instrument
Identification Code
|
Ordinary shares of £0.002
ISIN: GB00BJQTGV64
|
|
b.
|
Nature of the transaction
|
Sale
|
|
c.
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
£1.01
£0.98
|
60,000
140,000
|
|
|
|
|
e.
|
Date of the transaction
|
5 & 6 April 2022
|
|
f.
|
Place of the transaction
|
AIM Market of the London Stock Exchange
|